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Objective. Loss of regulation of vascular endothelial growth factor (VEGF) production and action disturbs vascular
homeostasis leading to pathology. Primary varicose veins (VVs) demonstrate aberrant production/release of VEGF. Our aim
was to examine transcription of genes for VEGF (VEGF121/VEGF165) and its receptors (KDR, flt-1, s.flt-1) in VVs, in
relation to underlying venous incompetence.
Materials and methods. Samples of varicose (n ¼ 83, 18 patients) or normal (n ¼ 14, five subjects) great saphenous vein
were divided into segments, determined by anatomical position from the sapheno-femoral junction (SFJ). SFJ and segmental
incompetence were determined from duplex scans. Gene transcripts were amplified by RT-PCR, analysed by scanning
densitometry, and the levels of transcription determined by ratio to control gene GADPH-3 (GAP-3).
Results. VEGF121/165, KDR and flt-1 transcription was elevated in VVs overall (p , 0.001), and in VVs with an
incompetent SFJ (p , 0.001), but not when the SFJ was functional; s.flt-1 was unaltered. Notably, gene transcription was
unaffected by segmental position, or incompetence. Position below the SFJ correlated with increased transcription of s.flt-1
when the SFJ was incompetent (p , 0.04), and s.flt-1 and VEGF121 when the segment was incompetent (p , 0.03).
Conclusions. SFJ incompetence is associated with altered transcription of VEGF and its receptors reflecting an aetiological
mechanism or later stage of disease development. Altered VEGF121 and s.flt-1 transcription may be an early event in
varicogenesis.
Key Words: Varicose veins; Vascular endothelial growth factor; KDR; flt-1; s.flt-1; Sapheno-femoral junction; Venous
incompetence.
Introduction
The pathophysiology of primary varicose veins (VVs)
is complex. Numerous risk factors have been
described,1 – 3 aetiological and clinical studies per-
formed,4 – 11 and detailed pathological examinations
of anatomy, enzymes and cytokines in the vessel wall
undertaken,12 – 22 all of which have aided our greater
understanding of the disease. A causative mechanism
has yet to be elucidated. Current evidence suggests
that the disease starts as the result of a ‘mechanical’
problem such as descending valvular incompetence or
arterio-venous fistula,23 – 26 or more likely, from a
‘cellular’ defect such as dysfunction of the endo-
thelium or smooth muscle cell.27 – 32 It is likely that
during the subsequent process(es) of disease pro-
gression, both types of mechanism play a role.
The macroscopic examination of VVs shows them
to be patchy,2,25 but why should there be patches of
varicosity in continuity with seemingly ‘normal’
sections of tissue? A potential explanation could be a
central molecular abnormality (a ‘cellular’ defect)
which, although not sufficient to be pathological in
itself, if exacerbated by localised factors such as
disturbed flow due to anatomical or positional
features within the vein (an anatomical or ‘mechanical’
defect), might then render that area susceptible to
pathological changes. Here, clear candidates for an
early or initiating problem might be the endothelial
cell and/or the smooth muscle cell. A number of
factors have focused our particular interest. Firstly,
many of the changes seen in the walls of VVs might
reasonably appear to be secondary to the action of
cytokines secreted from the smooth muscle cell.
Secondly, changes in the flow or chemistry of blood
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within the ‘pre-varicose’ vein may lead to a temporary
hypertensive intra-luminal state, derived from either
an anatomical abnormality, an aberrant cellular
response, or simply reduced return blood flow due
to a lack of physical movement, the appropriate
homeostatic response to which should be to relieve
‘symptoms’ by mediating dilatation and/or an
increase in vessel wall permeability. The resulting
venous stasis, relative hypoxia, reduction in pH33,34
and increase in oxidative metabolites and reactive
oxygen species alone could be damaging to the vessel
wall35 – 37 and additionally, lead to the activation of
monocytes,38 macrophages39 and neutrophils34,40 and
the release of pro-inflammatory cytokines.36 Irrespec-
tive of mechanism, the basis for varicogensis might be
seen initially in the loss of maintenance or regulation
of venous homeostasis. The subsequent aberrant
control of venous reactivity could thus lead to, and
also help to explain, many of the tissue and cellular
alterations observed pathologically in VVs.
Vascular endothelial growth factor (VEGF) plays
a central role in maintaining vascular integrity and
reactivity by, in concert with nitric oxide, mediating
vaso-permeability and dilatory responses.41 – 43
Increased intra-luminal pressure should elicit a
compensatory response of dilatation with/without
increased vessel permeability. Previously, however,
patients with primary VVs demonstrated a loss of
the release of VEGF following a mild, experimen-
tally-induced venous stasis that was seen in normal
subjects.44 Plasma nitric oxide was reduced signifi-
cantly in VVs suggesting that a fault in VEGF
maintenance of vascular reactivity might be
involved. An imbalance in vaso-active mediators
resulting in reduced active vessel wall tension has
been suggested previously,31 whereby reduced
smooth muscle action may result from dysfunction
of the endothelium.27 – 30 These studies, however, did
not examine VEGF, produced by the vascular
smooth muscle,41,42 or its inter-relation with nitric
oxide, produced by the vascular endothelium.43
In terms of VEGF, VVs may have a reduced ability
to produce this molecule, or to respond appropriately
to it once produced. Extending our earlier obser-
vations on VEGF our aim was to examine the activity
(transcription) of the genes for VEGF (the soluble
isoforms VEGF121 and VEGF165) and its receptors
(KDR, flt-1, and the soluble isoform of flt-1, s.flt-1) in
primary VVs. We have also examined alterations in the
transcription of VEGF and its receptors in relation to
both the underlying venous incompetence, and com-
petence at the SFJ.
Methods
Subjects and informed consent
This study was conducted with approval of the Joint
UCL/UCLH Committees on the Ethics of Human
Research. With informed consent, samples of VVs
were obtained from patients undergoing sapheno-
femoral ligation and stripping of the great saphenous
vein (GSV) as treatment for primary VVs. The
diagnosis of primary VVs was made by the referring
surgeon, confirmed by the vascular technologist
undertaking the venous duplex scan and was defined
as clinically evident VVs (CEAP grade II or above)
where; (i) no previous surgery had been undertaken,
(ii) there was no evidence of a thrombotic event in the
deep veins, and (iii) there was no differential diag-
nosis. Examination of reflux at the sapheno-femoral
junction (SFJ) and GSV was undertaken with patients
standing and reported as incompetence only when the
duration of reflux exceeded 0.5 s duration. The
position of incompetent venous segments was cross-
checked against the duplex scan report following
removal of the vein. Prior to operation, a record was
made from the duplex scan of patterns of venous
incompetence and distribution of varicosities. Samples
of normal control vein were obtained from patients
undergoing cardiac bypass procedures and who had
no symptoms or clinically evident signs of varicose
disease in either limb; veins were confirmed to be
normal by a pre-operative duplex scan, showing that
the vessel was disease-free and without valvular
incompetence in any segment.
Sample collection and preparation
VVs or normal GSV, collected at operation, were
placed immediately in ‘ice-cold’ Soltrane kidney
perfusate solution (1 L containing; 8.6 g potassium
citrate, 8.2 g sodium citrate, 33.8 g mannitol, 10.0 g
magnesium sulphate, 80 mmol potassium, 84 mmol
sodium, 41 mmol magnesium, 54 mmol citrate,
41 mmol sulphate, osmolarity 480 mOsm, pH 7.1;
Baxter), packed on ice and transferred to the labora-
tory. With careful handling, always on ice and in
perfusate solution, traumatised ends of veins were
trimmed and the vein divided in to a maximum of five
equally-sized segments from the proximal to distal
ends; segments coded (1) ‘proximal’, (2) ‘proximal-
mid’, (3) ‘mid’, (4) ‘mid-distal’, and (5) ‘distal’; Fig. 1.
Due to the variability of length of vein stripped, and to
ensure that segments originated anatomically, from
similar sites (for grouped analyses), the number of
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segments taken were determined according to the
extent of stripping of the GSV, and as follows; to
below-knee—five segments, to just above-knee—four
segments, and to the mid-thigh—three segments; see
Fig. 1. Segments were matched to the duplex scan to
determine if competent (showing no reflux), or
incompetent (showing reflux). Then, 100–300 mg
samples from each segment were flash-frozen in liquid
nitrogen and stored before processing at 280 8C.
Frozen samples were crushed in a pestle and mortar
pre-cooled, and maintained cool, with liquid nitrogen,
the resultant powder was dissolved directly in Trie
Reagent (Sigma, UK), 1 ml per 50–100 mg of starting
tissue. Total cellular RNA was extracted according to a
standard protocol (Sigma, UK), re-suspended in 50 ml
of sterile, de-ionised, nano-pure, RNAse-free water
and stored at 220 8C prior to use. Complimentary
DNA (cDNA) was prepared from 4 mg of total RNA in
a 40 ml reaction, according to a standard protocol
(Gibco, UK), and stored at 220 8C before analysis.
Analysis of gene transcription
Transcripts from all genes examined were amplified
by RT-PCR and analysed by scanning densitometry
(measured as total integrated optical density, IOD)
using LabWorks Imaging and Acquisition software
(UVP, Cambridge, UK). Levels of gene transcription
were determined from ratios of test gene PCR band
IOD and those of the control house-keeping gene
glycerylaldehyde 3-dehydrogenase (GAP-3). Primers
sets for all genes studied were designed to enable all
PCR reactions to be undertaken simultaneously and
within the same PCR machine. Briefly, 2 ml of sample
cDNA (0.1–0.4 mg/ml) were amplified in a 50 ml
reaction using ‘hot start’ with Taq polymerase (Gibco,
UK) in a Techne Genius Thermocycler (Jencons PLS,
UK) and according to a standard protocol. Amplifica-
tion was for 35 cycles of 94 8C for 45 s, 58 8C for 45 s,
and 72 8C for 60 s. Primers were as follows; (a) VEGF;
for the amplification of VEGF, a single set of primers
were used that were designed to be able to amplify the
soluble forms VEGF121 and VEGF165 within a single
reaction—CATCCTGTGTGCCCCTGATG (sense),
TTCCTCCTGCCCGGCTCAC (anti-sense); (b) KDR—
AGACTTTGAGCATGGAAG (sense), CCATTCCAC-
CAAAAGATG (anti-sense); (c) flt-1 and s.flt-1; a single
sense primer was used in conjunction with separate
anti-sense primers—TCATGAATGTTTCCCTGCAA
(sense), flt-1 GTGCTGCTTCCTGGTCCTAA (anti-
sense), s.flt-1 TTTGTTGCAGTGCTCACCTC (anti-
sense); (d) GAP-3—GCCAAAAGGGTCATCATCTC
(sense), TTTCTAGACGGCAGGTCAGG (anti-sense).
For all samples, at least two separate PCR reactions
were undertaken and the average IOD ratios from
repeated experiments used for further analysis.
Statistical analysis
Ages of individuals are presented as median values
with range in parenthesis, and comparisons between
groups were made by a Mann–Whitney U test.
Experimentally-obtained results for levels of gene
transcription were of a similar- and normal-shaped
distribution, as determined by a Kolmogorov–Smir-
nov one-sample test of normality, and descriptive
exploration and analysis of Skewness, and are pre-
sented as mean (s.e.m.) values. Comparisons of the
levels of gene transcription between experimental
groups were made by one-way or Kruskal–Wallis
analysis of variance (ANOVA). Comparisons of
differences in gene transcription in vein sections per
position, from proximal to distal (see Section 2), were
made by one-way ANOVA with Bonferroni’s correc-
tion to identify differences between individual group
means. Also, to examine for possible correlations
between position (proximal–distal; sections 1–5) and
levels of gene transcription, results were analysed by
Kendall’s bivariate correlation. All tests (where appro-
priate) were two-tailed; p , 0:05 was considered to be
statistically significant; actual p values are reported to
three decimal places to p , 0:001:
Fig. 1. Position of segments of VVs obtained for analysis.
‘Position’, position from the SFJ; ‘Section’, section number;
‘Stripped LSV’, indicates the extend of stripping of the LSV
undertaken at operation with corresponding numbering of
sections and respective segmental position from the SFJ.
Section numbering and position were performed to match
anatomical positions of sections taken for analysis, and to
enable cross-reference to duplex scans to determine compe-
tency (reflux or not) of the section at the position taken.
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Results
Table 1 summarises patient demographics, and the
samples obtained and used for analysis in this study.
In brief, GSV was obtained from 18 individuals with
primary VVs resulting in a total of 83 samples
available for analysis. Of these, seven had an intact
and functional SFJ (four male:three female; 29
samples), and 11 had an incompetent SFJ (three
male:eight female; 54 samples). Five normal GSVs
were obtained (three male:two female), resulting in a
total of 14 samples available for analysis.
Varicose and normal veins
Overall, including all VVs and irrespective of compe-
tence at the SFJ, patients from whom samples of VVs
were obtained were younger than those from whom
samples of normal veins were taken (p , 0:03; Mann–
Whitney U; Table 1). [This difference was largely
accountable by the sub-group of individuals with VVs
that had an incompetent SFJ whose median age was
younger than those with VVs and a competent SFJ
which, when grouped for age overall, was younger
than those from whom normal veins were obtained;
see analysis below, and Table 1]. When VEGF and its
receptors were examined, the levels of gene transcrip-
tion for all genes, except for s.flt-1, were elevated in
sections of VVs compared to those from normal veins
(Fig. 2); VEGF121, VEGF165 and KDR (all, p , 0:001),
flt-1 ðp , 0:002Þ; s.flt-1 ðp ¼ 0:743Þ; all Kruskal–Wallis
test.
Competence at the sapheno-femoral junction
Results from VVs were now sub-divided and analysed
specifically in conjunction with competence at the SFJ.
Individuals in whom the SFJ was intact and functional
(as determined from duplex scan) had a greater, but
not statistically significant, median age than those in
whom the SFJ was incompetent and showing reflux
(Table 1). As with VVs overall compared to normal
veins, transcription of s.flt-1 was unaltered in VVs by
competence at the SFJ. In sections from VVs where the
SFJ was incompetent the levels of transcription of
VEGF121, VEGF165, KDR, and flt-1 were elevated
compared to either those where the SFJ was functional
(all p , 0:001), or to normal veins (all p , 0:001), Fig. 3.
In contrast, when the SFJ was competent, gene
transcription was similar to that in normal veins for
VEGF165, KDR, flt-1 and s.flt-1. However, transcription
of the VEGF121 isoform was elevated (p , 0:02; see
Fig. 3), although not to the levels seen when the SFJ
was incompetent.
Table 1. Patient demographics and numbers of samples obtained from these individuals used for analysis of levels of gene transcription
Varicose veins Normal veins
Competent SFJ Incompetent SFJ Total
Patients, n 7 11 18 5
Median age (range) yrs 62 (28–69) 43 (27–58) 48* (27–69) 63 (50–72)
Male, n 4 3 7 3
Female, n 3 8 11 2
Samples, n 29 54 83 14
Male, n 15 15 30 7
Female, n 14 39 53 7
SFJ, sapheno-femoral junction. *p , 0:03 vs normal veins, Mann–Whitney U test.
Fig. 2. Transcription of VEGF (A) and its receptors (B) in
sections of normal and VVs. IOD Gene:GAP-3 is the ratio of
the integrated optical density (IOD), determined by scanning
densitometry, of the specific gene product (VEGF121/165,
KDR/flt-1/s.flt-1) to its corresponding product for GAP-3.
Shaded bars, normal vein sections; open bars, sections from
VVs. Bars represent means values, and error-bars are s.e.m.
(n ¼ 83 sections analysed from VVs; n ¼ 14 sections ana-
lysed from normal vein sections; all with two PCR analyses
per section for each gene examined). *p , 0:001
and †p , 0:002 vs normal vein sections, Kruskal–Wallis test.
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Segmental venous incompetence
To enable examination of levels of gene transcription
in conjunction with vein competence, results were
now grouped and analysed as follows. The duplex
scan for each patient was examined and the position of
each analysed section of vein was determined. By
cross-reference, it was determined whether the section
of vein had originated from a position where the vein
was either (i) competent and showing no reflux, or (ii)
incompetent and showing reflux, as shown by the
duplex scan. Duplex scans performed on normal
individuals demonstrated all sections of vein to be
competent. The results are presented in Fig. 4. Of the
83 sections obtained from VVs, 16 sections were
derived from a position where the vein was compe-
tent, and 67 sections where the vein was incompetent.
In comparison to sections of normal vein, sections
that were competent and obtained from VVs had
elevated levels of transcription of VEGF121 ðp , 0:02Þ;
VEGF165 ðp , 0:006Þ; and KDR ðp , 0:007Þ; Fig. 4; flt-1
transcription was also elevated, although not signifi-
cantly. As previously, transcription of s.flt-1 was
unaltered. Similarly, in incompetent sections of VVs,
the levels of transcription of all genes were elevated
compared to sections from normal veins, except s.flt-1
(VEGF121, VEGF165, KDR and flt-1, all p , 0:001).
Transcription of VEGF165 and the receptors KDR,
flt-1 and s.flt-1 were similar in competent, and
incompetent sections obtained from VVs (Fig. 4). Of
note though, there was a trend for greater transcription
of VEGF121 in incompetent sections of VVs as opposed
to competent VVs sections (p ¼ 0:074; see Fig. 4).
Position and segmental competence
Transcription of genes was now examined according
to the segmental position from the SFJ, i.e. proximal,
proximal-mid, mid, mid-distal and distal, as described
in Section 2; see Fig. 1. There was little or no difference
in the levels of transcription of VEGF121, VEGF165,
KDR or flt-1 according to position below the SFJ. There
was an indication that levels of s.flt-1 transcription
increased with increasing distance from the SFJ. On
further analysis, there was a direct correlation for
increased transcription of s.flt-1 with descending
position from the SFJ (p , 0:04; Kendall’s bivariate
correlation; Fig. 5). No other gene product demon-
strated any correlation with position from the SFJ.
To investigate this further, similar analyses were
Fig. 3. Transcription of VEGF (A) and its receptors (B) in
sections of normal veins (light-shaded bars), and VVs from
individuals with a competent SFJ (dark-shaded bars), or
incompetent SFJ (open bars). IOD Gene:GAP-3 is the ratio of
the integrated optical density (IOD), determined by scanning
densitometry, of the specific gene product (VEGF121/165,
KDR/flt-1/s.flt-1) to its corresponding product for GAP-3.
Bars represent means values, and error-bars are s.e.m.
(n ¼ 14 sections from normal veins; n ¼ 29 sections analysed
from VVs with a competent SFJ; n ¼ 54 sections analysed
from VVs with an incompetent SFJ; all with two PCR
analyses per section for each gene examined). *p , 0:001 vs
competent SFJ, and vs normal veins; †p , 0:02 vs normal
veins; all Kruskal–Wallis test. SFJ, sapheno-femoral junction.
Fig. 4. Transcription of VEGF (A) and its receptors (B) in
sections of normal veins (light-shaded bars), and VVs where
the section of vein was competent (dark-shaded bars), or
incompetent (open bars). IOD Gene:GAP-3 is the ratio of the
integrated optical density (IOD), determined by scanning
densitometry, of the specific gene product (VEGF121/165,
KDR/flt-1/s.flt-1) to its corresponding product for GAP-3.
Bars represent means values, and error-bars are s.e.m.
(n ¼ 14 sections from normal veins; n ¼ 16 competent
sections from VVs; n ¼ 67 incompetent sections from VVs;
all with two PCR analyses per section for each gene
examined). *p , 0:001; †p , 0:02; ‡p , 0:006 and §p , 0:007
vs sections from normal veins; all Kruskal–Wallis test.
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performed with results sub-divided by (i) competence
at the SFJ, and (ii) segmental incompetence.
When the SFJ was competent and functional,
transcription of any one gene was not affected by the
position from which the vein segment had been taken.
When the SFJ was incompetent there was a correlation
between position below the SFJ and increased tran-
scription of s.flt-1 (p , 0:05; Fig. 6). When this analysis
was repeated but this time examining competence of
the segment, a similar pattern was observed. For
competent segments, gene transcription was unaf-
fected by position and no correlation was seen. When,
however, the segment was incompetent and showing
reflux, there was again increased s.flt-1 transcription
correlated to descending position from the SFJ
(p , 0:03; Fig. 7(A)). In addition, there was a similar
correlation in these segments of increasing transcrip-
tion of VEGF121 with descending position from the SFJ
(p , 0:02; Fig. 7(B)).
Discussion
Primary VVs are widely accepted to be a chronic disease
which becomes more prevalent later in life;4,6,23,45 they
also occur in younger, primarily female individuals1,23
and associated with pregnancy.4, 46, 47 Their pattern of
appearance suggests that the underlying process
‘accumulates’ over time eventually overtaking repair
mechanism(s) resulting in ‘dilated, elongated or
tortuous veins’48 that are ‘pouched and thickened’.49
The control of transcription of genes involved in
maintaining vascular reactivity might become altered
either as a causative mechanism, or simply as a result
of the pathological process(es). Examination of such
genes may help to elucidate the mechanism under-
lying VVs development. As VVs occur in many
patients where the SFJ is competent,23 the importance
of the failure of the SFJ valve as an initiating
mechanism50 remains to be clarified. This study is
the first to examine changes in gene transcription with
distance below the SFJ and in direct association with
underlying venous incompetence. We address for the
first time alterations in patterns of gene activity
(transcription) in relation to competence at the SFJ.
We have examined the transcription of VEGF (soluble
isoforms VEGF121, VEGF165), and its receptors (KDR,
flt-1, s.flt-1) in segments of VVs matched anatomically
in descending position from the SFJ, and in relation to
underlying venous segmental incompetence, and SFJ
status.
Fig. 5. Transcription of s.flt-1 in VVs overall by segmental
position. s.flt-1 transcription increased with descending
position from the SFJ, p , 0:04 (Kendall’s Bivariat Cor-
relation). IOD Gene:GAP-3 is the ratio of the integrated
optical density (IOD), determined by scanning densito-
metry, of s.flt-1 gene product to its corresponding product
for GAP-3. Bars represent means values, and error-bars are
s.e.m. Position below the SFJ (number of sections per
position); Prox-proximal ðn ¼ 18Þ; Prox-Mid—proximal to
mid ðn ¼ 18Þ; Mid-mid ðn ¼ 18Þ; Mid-Dist—mid to distal
ðn ¼ 15Þ; Dist-distal ðn ¼ 14Þ; all with two PCR analyses per
section examined. SFJ, sapheno-femoral junction.
Fig. 6. Transcription of s.flt-1 by segmental position in VVs
in the presence of an incompetent SFJ. s.flt-1 transcription
increased with descending position from the SFJ, p , 0:05
(Kendall’s Bivariat Correlation). IOD Gene:GAP-3 is the ratio
of the integrated optical density (IOD), determined by
scanning densitometry, of s.flt-1 gene product to its
corresponding product for GAP-3. Bars represent means
values, and error-bars are s.e.m. Position from the SFJ
(number of sections per position); Prox-proximal ðn ¼ 11Þ;
Prox-Mid—proximal to mid ðn ¼ 11Þ; Mid-mid ðn ¼ 11Þ;
Mid-Dist—mid to distal ðn ¼ 11Þ; Dist-distal ðn ¼ 10Þ; all
with two PCR analyses per section examined. SFJ, sapheno-
femoral junction.
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For VVs overall, transcription of VEGF121/165, KDR
and flt-1 was elevated compared to normal veins
(Fig. 2). This suggests a potential for greater plasma
VEGF and VEGF receptor expression. Protein was not
measured here as levels of soluble VEGF isoforms
cannot be determined accurately from tissue seg-
ments; receptor expression could be analysed by
immuno-histochemistry, but this study was under-
taken to determine transcriptional activity. Despite
this, although transcription was increased, our earlier
experiments found levels of plasma VEGF not to be
elevated in VVs;44 [elevated plasma VEGF has been
reported in VVs but primarily in conjunction with skin
changes.51] Barber and co-workers found reduced
contraction to endothelin-1 (ET-1) in VVs in vitro
associated with a decrease in ET-1 receptors, an effect
that seemed to be regulated at the transcriptional
level.52 Enhanced VEGF transcription but without
increased protein production44 might suggest a pro-
blem with translation to protein. Alternatively, if the
elevated levels of message (mRNA) detected here
were not of full-length, the resultant protein might
potentially be truncated and so unable to bind the
antibodies used previously for detection.44 Further
studies, therefore, should address the rates of trans-
lation of VEGF and its receptors to protein, and the
production of full-length mRNA transcripts.
The presence of VVs with levels of transcription
similar to normal veins, i.e. those VVs were the SFJ
was competent provides several explanations. Firstly,
aberrations in VEGF/receptor transcription may
simply not be a causative mechanism in VVs devel-
opment. In contrast, a fault in the control of VEG-
F/receptor transcription might be involved. For
example, receptor down-regulation (or induced
redundancy) in response to continued stimulation
(from enhanced VEGF expression) could result, in a
compromised ability to respond appropriately; as seen
previously with ET-1 receptors in VVs in vitro,52 an
effect which may have been initiated due to elevated
ET-1 production/exposure.52,53 A possible further
explanation for our results could be that VEGF/
receptor transcription is proportional to intra-luminal
pressure so when the SFJ is incompetent pressure
increases and transcription becomes proportionally
elevated. This would require that the pressure in VVs
in patients with an incompetent SFJ is greater than that
in those with a competent SFJ. However, this has yet to
be established. The altered pattern of VEGF/receptor
transcription seen might suggest SFJ incompetence
represents disease of a differing stage of development
i.e. later than when the SFJ is functional.
The ‘patchy’ nature of varicosities suggests disease
on-going at localised points. It seems likely that there
is a tissue-wide underlying molecular problem
throughout the vein, but that disease develops due
to other localised factors. To address this possibility,
we examined gene transcription in association with
competence or incompetence of each vein segment.
When examining segmental competence (rather
than SFJ), the pattern of transcription seen was
different. Transcription of VEGF121/165, KDR and flt-1
Fig. 7. Transcription of s.flt-1 (A) and VEGF121 (B) by
segmental position in incompetent segments of VVs. Tran-
scription of s.flt-1 ðp , 0:03Þ and VEGF121 ðp , 0:02Þ increased
with descending position from the SFJ (both, Kendall’s Bivariat
Correlation). IOD Gene:GAP-3 is the ratio of the integrated
optical density (IOD), determined by scanning densitometry,
of VEGF121 or s.flt-1 gene product to its corresponding
product for GAP-3. Bars represent means values, and error-
bars are s.e.m. Position from the SFJ (number of sections per
position); Prox-proximal ðn ¼ 17Þ; Prox-Mid—proximal to
mid ðn ¼ 16Þ; Mid-mid ðn ¼ 15Þ; Mid-Dist—mid to distal
ðn ¼ 12Þ; Dist-distal ðn ¼ 7Þ; all with two PCR analyses per
section examined. SFJ, sapheno-femoral junction.
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was of a similar level in both competent and
incompetent segments of VVs; however, in all seg-
ments (competent or incompetent), transcription was
elevated compared to normal veins (Fig. 4). Activation
of VEGF/receptor transcription as a homeostatic
response might, therefore, reflect an earlier event,
occurring prior to the development of incompetence
within the vein wall. It is considered that VEGF,
produced from the vascular smooth muscle in
response to for example, hypoxia or pressure, stimu-
lates production of nitric oxide from the vascular
endothelium which in turn, acts on the vascular
smooth muscle to generate a ‘loop’ mechanism to
mediate vascular reactivity.41 Again, as with ET-1,52,53
enhanced VEGF/receptor transcription in response to
‘stimulus’ (pressure, etc.), if not relieved or controlled,
might lead ultimately to reduced VEGF/receptor
activity and vein wall responses. Continued and
elevated VEGF/receptor expression (via the mechan-
ism described above,41) may lead to elevated pro-
duction of nitric oxide resulting in the generation of
other reactive oxygen species, and so contributing to
the further development of pathology. Overall thus, in
trying to maintain homeostasis, the activation of
VEGF/receptor transcription may itself become a
central part of the subsequent pathological process.
A surprising result was that transcription of s.flt-1
was similar in all samples/segments and unaffected
by varicosity or competence. The importance of
control of VEGF in the pathogenesis of vascular
disorders has been realised through observation of
the production of the soluble form of the VEGF flt-1
receptor, s.flt-1.54 In patients with peripheral artery
and cardiovascular diseases, plasma VEGF was raised
but s.flt-1 was significantly reduced,55,56 whilst in
patients with essential hypertension, the elevated
levels of both VEGF and s.flt-1 were reduced with
successful treatment of the hypertension.57 That s.flt-1
may control the action of VEGF directly has been
evidenced; the presence of s.flt-1 correlated inversely
with degree of phosphorylation (activation) of the
VEGF receptor KDR;58 and, hypoxia can both stimu-
late the production of VEGF41,42 and up-regulate s.flt-1
protein production, whilst down-regulating auto-
phosphorylation (hence, activation) of the membrane
flt-1 receptor.59 Increased oxygen tension might
stimulate, in conjunction with the production/release
of VEGF, an associated down-regulation of the
membrane flt-1 receptor in favour of s.flt-1 to control
the action of the VEGF produced.
In this study, although s.flt-1 transcription was
unaffected by varicosity or competence, we found
previously that s.flt-1 (protein) in the plasma of
patients with primary VVs was markedly elevated
above normal subjects.60 It is possible thus, that
steady-state levels of s.flt-1 transcription are ordinarily
maintained, but with control of VEGF action being
mediated via the rate of translation to protein. It would
be interesting to examine mRNA half-life and rates of
translation of s.flt-1 in our samples studied here.
Transcription of s.flt-1 increased in VVs overall with
descending position from the SFJ (Fig. 5), and
associated with incompetence at the SFJ (Fig. 6) but
not when the SFJ was competent. Similarly, this
pattern of increased s.flt-1 transcription was seen
descending from the SFJ in incompetent segments
(Fig. 7(A)). Therefore, if intra-luminal pressure
increases with descending position from the SFJ,
enhanced VEGF transcription might be expected and
accordingly, enhanced s.flt-1 transcription to mediate
VEGF action. However, we did not observe an increase
in VEGF transcription with descending position from
the SFJ, although this may be masked by the overall
elevated levels of VEGF transcription seen in VVs (Fig.
2). Alternatively, enhanced s.flt-1 transcription may
simply reflect an on-going pathological process.
Previously, we have observed that varicosities tend
to appear more distally, and at a position at, or below,
the underlying venous incompetence.61 Collectively,
the pattern of disease, in conjunction with alterations
in gene transcription, might reflect a process of
increasing pressure from proximal to distal, but with
disease and the appearance of varicosities developing
in a distal to proximal manner.
Descending position from the SFJ correlated in
incompetent segments with increased transcription
also, of VEGF121 (Fig. 7(B)); notably, the only gene to be
elevated transcriptionally in VVs with a competent SFJ
compared to normal veins (Fig. 3). The function of
VEGF121 is currently unclear, however, enhanced
VEGF121 transcription has been seen in other diseases
comprising an inflammatory component, this being
sporadic colorectal cancer.62
Altered transcription of VEGF and its receptors
(notably VEGF121 and s.flt-1) is associated in some part
with the processes of development, and may represent
an early event before the development of vessel wall
incompetence. Further investigation of VEGF and its
regulation is important if we are to understand more
fully the mechanisms responsible for VVs. Incompe-
tence of the SFJ may represent a disease of different
aetiology or a later stage of development in the
spectrum of VVs.
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